Mushrooms & Parkinson's Disease
3 compound classes
Erinacine A, ganoderic acids, and ergothioneine have each demonstrated dopaminergic neuroprotection in independent laboratory models — and a 2025 study validated ergothioneine across three model systems simultaneously.
He et al., Molecules, 2022 / Tng et al., Journal of Neurochemistry, 2025
Post-treatment works
erinacine A attenuated MPTP neurotoxicity even given after injury, not just before (Lee 2020)
OCTN1-dependent
ergothioneine protection of human iPSC dopaminergic neurons requires the OCTN1 transporter (Ng 2024)
Human cell evidence
Ng 2024 used actual patient-derived neurons from LRRK2 G2019S Parkinson's patients
He et al., Molecules, 2022 / Tng et al., Journal of Neurochemistry, 2025
View as image ↗The brain region that fails in Parkinson's disease — the substantia nigra — is home to a specific type of cell called a dopaminergic neuron. These neurons produce dopamine, a chemical that coordinates movement. Parkinson's disease destroys them progressively. By the time motor symptoms appear, roughly 60 to 80 percent of dopaminergic neurons in the substantia nigra are already gone. This is the target that mushroom compounds researchers have been studying, and three distinct classes of mushroom compounds have now shown they can protect dopaminergic neurons in controlled laboratory models: erinacine A from lion's mane mycelium, ganoderic acids and polysaccharides from reishi, and ergothioneine from culinary mushrooms of many species. This article is part of the broader cluster on mushrooms and Parkinson's disease neuroprotective research, within the larger pillar on mushrooms and brain health, focusing specifically on the molecular mechanisms behind these protective effects.
The evidence for all three is preclinical — meaning it comes from animal models and cell cultures, not from human Parkinson's disease trials. That is the right framing to maintain throughout. But preclinical evidence is where mechanistic understanding is built, and these mechanisms matter for understanding whether the compounds could eventually translate. For the epidemiological evidence connecting mushroom consumption and ergothioneine levels to Parkinson's risk in human populations, see Ergothioneine and Parkinson's Disease Risk: Evidence Review.
Key Takeaways
- Erinacine A, a compound found primarily in lion's mane mycelium, improved dopaminergic neuron survival in MPTP-induced Parkinson's mouse models in both pre-treatment and post-treatment conditions
- Post-treatment with erinacine A still attenuated MPTP-induced neurotoxicity, making the finding more clinically plausible — real treatment scenarios don't allow pre-dosing before injury
- Reishi (Ganoderma lucidum) extract improved locomotor performance and dopaminergic markers in MPTP mice via mitochondrial regulation and anti-neuroinflammation
- Ergothioneine enters dopaminergic neurons via the OCTN1 transporter and protects them from oxidative damage — the mechanism has been confirmed in human LRRK2 G2019S patient-derived iPSC neurons
- A 2025 study validated ergothioneine's protective effects across Drosophila, mouse, and human iPSC models simultaneously — the most multi-modal evidence to date
- Ergothioneine is found in virtually all edible mushroom species, not just lion's mane — making it the most broadly accessible dietary target among the three compound classes
The Compound Map: What Each Class Does and Where It Comes From
Before the mechanistic detail, here is a reference map of the three main compound classes and their evidence:
| Compound | Primary source | Core mechanism | Best model evidence |
|---|---|---|---|
| Erinacine A | Lion's mane mycelium | NGF stimulation + survival pathway activation | MPTP mouse pre/post-treatment (Li 2018, Lee 2020) |
| Ganoderic acids + polysaccharides | Reishi (Ganoderma lucidum) | Mitochondrial regulation + anti-neuroinflammation | MPTP mouse, two independent studies (Ren 2019, Ren 2022) |
| Ergothioneine | All culinary mushroom species | OCTN1-dependent ROS scavenging in dopaminergic neurons | Human iPSC + Drosophila + mouse (Ng 2024, Tng 2025) |
A comprehensive 2022 review by He et al. in Molecules surveyed all three compound classes alongside mushroom polysaccharides, identifying validated neuroprotective mechanisms across Parkinson's, Alzheimer's, and ALS models and mapping where the gaps in clinical translation remain.[1] That review provides the shared vocabulary for this field. The sections below go deeper into what each class has produced experimentally.
Erinacine A: The Lion's Mane Compound With MPTP Evidence
Erinacine A is a diterpene compound found primarily in the mycelium — the underground root-like network — of Hericium erinaceus, commonly known as lion's mane. It is distinct from hericenones, which are found in the fruiting body. This distinction matters for anyone evaluating lion's mane supplements, because most commercial products use fruiting body extract, and erinacines are concentrated in mycelium. The preclinical Parkinson's data involves erinacine-enriched mycelium specifically.
The foundational evidence comes from Li et al., whose 2018 systematic review documented that erinacine A-enriched H. erinaceus mycelia improved dopaminergic lesions and reduced oxidative stress in the striatum and substantia nigra of MPTP-treated mice.[2] MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin that selectively destroys dopaminergic neurons and is the most widely used chemical model of Parkinson's disease. Li's review also highlighted that erinacines penetrate the blood-brain barrier — a prerequisite for any orally administered compound to reach dopaminergic neurons directly.
Erinacine A stimulates nerve growth factor (NGF) production. NGF is a protein that promotes the survival, development, and maintenance of neurons, including dopaminergic ones. The relevant pathway here: Parkinson's disease is characterized by reduced neurotrophic support for dopaminergic neurons. Compounds that restore or augment NGF-driven survival signaling are therefore a plausible intervention point.
Post-Treatment Is More Clinically Relevant — and It Still Works
A 2020 study by Lee et al. added a critical refinement to the erinacine A data.[3] Most preclinical neuroprotection experiments are run as pre-treatment studies: the protective compound is given before the neurotoxin or injury is administered. That design shows whether the compound can prevent damage, not whether it can treat damage that has already begun.
Lee's team ran erinacine A as a post-treatment: giving it to mice after MPTP exposure, not before. Post-treatment with erinacine A still attenuated MPTP-induced neurotoxicity and improved dopaminergic neuron survival. The mechanism involved PAK1/AKT/ERK survival signaling pathways — cellular pathways that promote neuron survival rather than prevent initial injury.
This post-treatment finding is important because it more closely mirrors a real therapeutic scenario. Parkinson's disease is typically diagnosed after significant dopaminergic neuron loss has already occurred — there is no clinical setting where a preventive agent is started before disease onset based on a known MPTP exposure. A compound that works after the damage begins is more relevant to actual treatment scenarios than one that only prevents injury when given first.
Reishi: Mitochondrial Protection and Anti-Neuroinflammation
Ganoderma lucidum — reishi — has been studied in two independent MPTP mouse experiments that reached consistent conclusions from slightly different angles.
Ren et al., published in Frontiers in Aging Neuroscience in 2019, found that Ganoderma lucidum extract significantly improved locomotor performance in MPTP-treated mice and increased tyrosine hydroxylase expression in the substantia nigra pars compacta.[4] Tyrosine hydroxylase is the enzyme that converts tyrosine to L-DOPA, the precursor to dopamine — it is a direct marker of dopaminergic neuron health. Higher tyrosine hydroxylase expression means more surviving, functional dopaminergic neurons.
The mechanism in Ren 2019 centered on mitochondrial function and autophagy. Mitochondrial dysfunction is a core feature of Parkinson's disease pathology — dopaminergic neurons in the substantia nigra are particularly energy-demanding and therefore particularly vulnerable when mitochondria fail. The AMPK/mTOR and PINK1/Parkin signaling pathways that Ren 2019 identified regulate both mitochondrial quality control and the cell's autophagy process — the mechanism by which damaged mitochondria are cleared. Reishi extract appeared to improve both.
A second Ren et al. study, published in Nutrients in 2022, approached the same MPTP mouse model from the neuroinflammation angle.[5] In Parkinson's disease, activated microglia — the brain's immune cells — release inflammatory signals that accelerate dopaminergic neuron death. MPTP administration triggers this microglial activation. The 2022 Ren study found that Ganoderma lucidum extract significantly repressed MPTP-induced microglial activation, improved motor function, and protected dopaminergic function in the nigrostriatal pathway.
Two independent MPTP studies from the same research group, testing different mechanisms, arriving at the same protective outcome: this is the kind of replication that preclinical neuroprotection research needs but rarely produces. Reishi's neuroprotective effects in these models appear to operate via at least two distinct mechanisms — mitochondrial regulation and anti-neuroinflammation — which suggests the effect is not dependent on any single molecular target.
For more on how neuroinflammation is a shared mechanism across neurodegenerative diseases and which mushroom compounds address it, see ALS and Neuroinflammation: Can Mushrooms Help?.
Ergothioneine: The Compound That Reaches Dopaminergic Neurons Directly
Ergothioneine is categorically different from erinacine A and ganoderic acids in one important respect: it is not specific to any one mushroom species. King oyster, shiitake, button, cremini, portobello, and virtually every other culinary mushroom species contains ergothioneine. This makes it the most broadly accessible of the three compound classes from a dietary standpoint.
Halliwell et al., in a 2022 comprehensive review published in Neurochemistry International, documented the biological pathway that makes ergothioneine relevant to dopaminergic neurons specifically.[6] Ergothioneine enters cells via a dedicated transporter called OCTN1. That transporter is expressed in brain tissue, and dopaminergic neurons in the substantia nigra express OCTN1 — which means ergothioneine has a direct and specific entry route into the exact cell population that Parkinson's disease destroys.
Once inside, ergothioneine acts as an antioxidant and cytoprotectant. The substantia nigra is an extremely high-oxidative-stress environment — dopaminergic neurons generate reactive oxygen species during dopamine synthesis and metabolism, and they are exposed to elevated levels of iron, which catalyzes oxidative damage. Ergothioneine neutralizes reactive oxygen species and also chelates metal ions like iron and copper, reducing oxidative catalysis. The Halliwell review documented that ergothioneine achieves concentrations in brain tissue that are biologically active — not trace amounts, but levels sufficient to function as a meaningful antioxidant buffer.
Human Cell Evidence: LRRK2 Patient-Derived Neurons
The most directly relevant human evidence for ergothioneine's mechanism was published by Ng et al. in Antioxidants in 2024.[7] Their experiment used induced pluripotent stem cells (iPSCs) — cells reprogrammed from adult cells back to a stem-cell-like state — derived from actual Parkinson's disease patients carrying the LRRK2 G2019S mutation. These iPSCs were then differentiated into dopaminergic neurons, creating human neurons with real Parkinson's disease genetics.
Ng's team exposed these neurons to rotenone, a pesticide-derived mitochondrial toxin used to model dopaminergic neuron death. Ergothioneine protected the LRRK2 G2019S neurons from rotenone-induced toxicity. The team then confirmed that this protection required OCTN1: when they blocked OCTN1 with an inhibitor, ergothioneine's protective effect was eliminated. Protection was OCTN1-dependent, confirming the transporter mechanism Halliwell had described. Ergothioneine also protected human SH-SY5Y neuroblastoma cells from 6-OHDA toxicity, a second model of dopaminergic neuron injury.
This is the first human cell evidence of ergothioneine's mechanism in a Parkinson's disease context. Prior work had used animal cells or non-PD human cells. The Ng 2024 study used neurons with the actual genetic architecture of human Parkinson's disease. For a focused article on the OCTN1 transporter and its broader significance, see OCTN1: The Dedicated Transporter That Proves Ergothioneine Matters.
Multi-Model Validation Across Three Systems
Tng et al., published in the Journal of Neurochemistry in 2025, provided the most comprehensive multi-modal validation of ergothioneine's Parkinson's effects to date.[8] They tested ergothioneine treatment across three independent Parkinson's model systems simultaneously: Drosophila fruit flies with parkin and LRRK2 mutations, mouse PD models, and human LRRK2 G2019S iPSC-derived dopaminergic neurons.
Ergothioneine improved outcomes in all three. Flies showed better climbing scores and reduced dopaminergic neuron loss. Mouse models showed reduced pathological phenotypes. The human iPSC-derived neurons showed enhanced survival. The same compound, tested in three biologically distinct systems, produced the same protective direction of effect.
This multi-system consistency is why Tng 2025 is the most important single study in this cluster. The usual criticism of preclinical neuroprotection research is that findings fail to replicate across models — a result that holds in a mouse often evaporates in a different species or cell type. Tng tested all three simultaneously and all three pointed the same direction.
Why Ergothioneine Is the Broadest Target
The mechanism hierarchy that emerges from this evidence is worth stating directly. Erinacine A has strong MPTP data but requires lion's mane mycelium specifically — fruiting body products, which dominate the supplement market, may not contain meaningful erinacine A concentrations. Ganoderic acids require reishi and have two independent MPTP datasets. Ergothioneine requires nothing more exotic than eating mushrooms — any culinary mushroom species will provide it.
This makes ergothioneine the most realistic dietary target among the three. It is also the compound with the most recent and most rigorous mechanistic evidence, the OCTN1-dependent pathway confirmed in human PD patient-derived neurons. The other two compounds have preclinical MPTP data; ergothioneine has that plus human cell evidence with actual PD genetics.
None of this means eating mushrooms treats or prevents Parkinson's disease. No human clinical trial with dietary mushroom consumption or isolated ergothioneine supplementation has been run in a Parkinson's population. What the preclinical evidence provides is a mechanistic case: these compounds reach the right cells, via the right biological routes, and produce the right protective effects in model systems. For a practical species-by-species breakdown of which mushrooms carry the most research weight in this area, see Which Mushrooms Show Promise for Parkinson's?.
The Bottom Line
Three classes of mushroom compounds have demonstrated dopaminergic neuroprotection in laboratory models: erinacine A from lion's mane mycelium via NGF stimulation and survival signaling, ganoderic acids and polysaccharides from reishi via mitochondrial regulation and anti-neuroinflammation, and ergothioneine from culinary mushrooms of many species via OCTN1-dependent transport and antioxidant activity in dopaminergic neurons. The 2024 and 2025 human iPSC and multi-model evidence for ergothioneine is the most mechanistically direct evidence available, though no human Parkinson's clinical trial has tested any of these compounds.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2RTHM-00973·Li, I-Chen et al. (2018). “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines..” Behavioural neurology.Study breakdown →PubMed →↩
- 3RTHM-01229·Lee, Kam-Fai et al. (2020). “Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson's Disease..” Antioxidants (Basel.Study breakdown →PubMed →↩
- 4RTHM-01118·Ren, Zhi-Li et al. (2019). “Ganoderma lucidum extract ameliorates MPTP-induced parkinsonism and protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis..” Acta pharmacologica Sinica.Study breakdown →PubMed →↩
- 5RTHM-01609·Ren, Zhili et al. (2022). “Ganoderma lucidum Modulates Inflammatory Responses following 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice..” Nutrients.Study breakdown →PubMed →↩
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8RTHM-02195·Tng, Teddy J W et al. (2025). “Ergothioneine Treatment Ameliorates the Pathological Phenotypes of Parkinson's Disease Models..” Journal of neurochemistry.Study breakdown →PubMed →↩